Close Menu
  • Homepage
  • Local News
  • India
  • World
  • Politics
  • Sports
  • Finance
  • Entertainment
  • Business
  • Technology
  • Health
  • Lifestyle
Facebook X (Twitter) Instagram
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
Facebook X (Twitter) Instagram Pinterest
JHB NewsJHB News
  • Local
  • India
  • World
  • Politics
  • Sports
  • Finance
  • Entertainment
Let’s Fight Corruption
JHB NewsJHB News
Home»Finance»Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Pill
Finance

Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Pill

January 2, 2026No Comments3 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Pill
Share
Facebook Twitter LinkedIn Pinterest Email

We not too long ago revealed 10 Shares on Jim Cramer’s Radar.  Novo Nordisk A/S (NYSE:NVO) is among the shares on Jim Cramer’s radar.

Danish pharmaceutical agency Novo Nordisk A/S (NYSE:NVO) scored a significant win earlier this month after it secured the Meals and Drug Administration’s (FDA) approval for its weight reduction capsule. The approval made the Wegovy capsule the primary of its form, and it led to the agency’s shares closing 7.30% greater. The approval marked a key win for Novo Nordisk A/S (NYSE:NVO) because the agency has reportedly struggled in opposition to Eli Lilly within the weight reduction drug market. Following the Wegovy capsule approval, the pharmaceutical firm moved quick, as a report from the Chinese language outlet Yicai recommended that Novo Nordisk A/S (NYSE:NVO) had minimize the costs of its highest dosage Wegovy medicine in half in some Chinese language provinces. After the approval, BMO Capital reiterated a Market Carry out ranking and a $46 share worth goal for the corporate. The monetary agency outlined that Novo Nordisk A/S (NYSE:NVO) may gain advantage from a first-mover benefit within the oral weight reduction drug market and added that it may face aggressive challenges sooner or later. Cramer shared his personal distinctive tackle the matter, as he commented that Novo Nordisk A/S (NYSE:NVO) would possibly see resistance from physicians relating to taking away market share from Eli Lilly:

Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)'s Weight Loss Pill
Jim Cramer Shares Key Caveat For Novo Nordisk (NVO)’s Weight Loss Tablet

“Now, keep in mind, {that a} capsule is way most well-liked within the nation, versus the shot. If you’re taking Wegovy, then folks will transfer over, shortly migrate over to Wegovy capsule. . .let’s say you’re taking Mounjaro proper now, Eli Lilly, they’re reluctant to say pay attention it’s best to go do Wegovy. As a result of what they’ll say is pay attention, you tolerate Mounjaro, and we simply care about toleration. And that’s been the way in which issues go. And I believe individuals who suppose, wow, there are people who find themselves going to be actually excited to maneuver over to the capsule. Their recommendation from the docs goes to be, no, there may very well be totally different reactions. And apparently the doses are so excessive, that there are some totally different adjustments in eating regimen that you just might need to do. We don’t know sufficient about what the unintended effects are, we all know this. The career simply doesn’t such as you to change from one drug to a different.

Source link

Caveat Cramer Jim key Loss Nordisk Novo NVOs Pill shares Weight
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Related Posts

Target (TGT) Reports Q4 Net Sales of $30.5B, Full-Year Adjusted EPS of $7.57

March 8, 2026

2 AI Stocks She Just Bought After the Tech Pullback

March 8, 2026

Is Marvell Finally Closing the Gap on Broadcom? Cramer Thinks So

March 8, 2026

AI Could Reignite Internet Traffic as Price Compression Persists

March 8, 2026
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

The mind behind Lakshya Sen’s All England run | Badminton News

March 8, 2026

Colorado Buffs women’s basketball vs. West Virginia in Big 12 semifinals

March 8, 2026

Jeffrey Epstein Prison Guard Googled Him Before Death, DOJ Reveals

March 8, 2026

Target (TGT) Reports Q4 Net Sales of $30.5B, Full-Year Adjusted EPS of $7.57

March 8, 2026
Popular Post

Watch: ‘Need to reverse that a little bit’ : Steven Gerrard reacts to Mohamed Salah’s comments after Liverpool’s 3-3 Premier League draw against Leeds United | Football News

India’s services growth slumped to 6-month low in September on cooling demand: PMI

CU Buffs start fast, fall short vs. No. 25 BYU – JHB

Subscribe to Updates

Get the latest news from JHB News about Bangalore, Worlds, Entertainment and more.

JHB News
Facebook X (Twitter) Instagram Pinterest
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
© 2026 Jhb.news - All rights reserved.

Type above and press Enter to search. Press Esc to cancel.